POSTMENOPAUSAL OSTEOPOROSIS

绝经后骨质疏松症

• 批准号: 6265508
• 负责人: NORMAN L BELL
• 金额: $ 1.74万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6265508
• 关键词: bone density; bone fracture; clinical research; drug adverse effect; drug screening /evaluation; estrogen inhibitor; female; human subject; human therapy evaluation; osteoporosis; postmenopause; women's health

To establish the effect of long-term treatment with raloxifene, compared with placebo, on the rate of new vertebral fractures in osteoporotic post- menopausal women with and without prevalent vertebral fractures. To establish the safety of chronic administration of raloxifene in post- menopausal women with osteoporosis. To establish the effect of long-term treatment with raloxifene, compared with placebo, on lumbar spine and femoral neck bone mineral density (BMD) in postmenopausal women with osteoporosis.

确定雷洛昔芬长期治疗与安慰剂相比对伴有和不伴有普遍椎骨骨折的绝经后骨质疏松妇女新发椎骨骨折发生率的影响。 确定绝经后骨质疏松妇女长期服用雷洛昔芬的安全性。 在绝经后骨质疏松症妇女中，与安慰剂相比，确定雷洛昔芬长期治疗对腰椎和股骨颈骨密度（BMD）的影响。